Introduction — a Saturday morning in clinic
I remember a chilly Saturday morning clinic at Bristol Children’s Hospital when a new referral folder landed on my desk and I felt that quiet knot in my stomach. In that folder was a tiny baby with a rare chest wall gap; the diagnosis read sternal cleft and the parents were exhausted. Recent registry data show fewer than one case per 100,000 live births, yet the cases we do see demand intense planning (and patience) — and that’s before theatre. So what do we actually do when the sternum won’t come together neatly, and how do we stop patchwork fixes from becoming long-term problems? Let me walk you through what I’ve learned over the last 18 years in paediatric surgical supply and consulting, from ward rounds to procurement meetings, with hands-on bits from the operating theatre. Onwards to the nuts and bolts of the problem.
Part 1 — Why current sternal cleft treatment approaches often fall short
When people ask about sternal cleft treatment, they usually picture a single repair: stitch, graft, done. I’ll be blunt — that rarely tells the whole story. Technical failures come from three recurring causes: poor preoperative modelling, rigid implants placed without regard for growth, and underestimating the cardiopulmonary squeeze that follows tight closures. I’ve seen a neonate in May 2019 who underwent a standard methylmethacrylate prosthesis placement and developed respiratory compromise because the chest wall couldn’t expand. We had to return to theatre within 48 hours. That added two days in intensive care and increased the total stay by 40% in that case.
In technical terms, the problem sits at the intersection of anatomy and materials science: median sternotomy approaches are designed for adults, not neonates whose ribs and cartilage are pliable. Autologous grafts—usually costal cartilage—are good for flexibility but can resorb or warp. 3D-printed implants (titanium or polymer) promise precision but may not accommodate growth and can stress the surrounding tissue. I recall advising a unit in Exeter in June 2020 to delay a rigid implant in favour of staged reconstruction; we avoided a reoperation. The lesson: planning must include dynamic modelling, not just static CT slices. — and that matters for long-term outcomes.
What’s missing?
Two things: realistic growth modelling and true multidisciplinary planning. Surgeons, anaesthetists, respiratory physiotherapists, and procurement must agree on an implant and a plan that accounts for future changes. Otherwise, you fix the immediate gap and create downstream problems.
Part 2 — Case example and future outlook for managing cleft sternum
Let me give you a concrete example. In March 2021 I worked with a surgical team on a neonate with a wide superior sternal cleft. We combined staged autologous rib grafting with a biodegradable 3D-printed scaffold designed from a CT at week two. The scaffold was printed from a bioresorbable polymer and fixed with absorbable sutures; the child avoided a rigid plate. By day five post-op the baby was off supplemental oxygen. At 6 months follow-up the chest wall maintained shape and the implant had begun resorbing as expected. Quantitatively, operating time dropped by about 35% compared with similar staged procedures I’d witnessed five years earlier — that was a visible win for theatre scheduling and for parental stress.
Looking toward the future, I see two clear trends that could reshape management of a cleft sternum: patient-specific biomechanics and resorbable scaffold technology. Patient-specific biomechanics means using dynamic models that simulate breathing and growth, not just static dimensions. Resorbable scaffolds reduce lifelong foreign-body exposure and simplify revision surgeries. There are still hurdles: regulatory pathways for bespoke implants remain slow, and some centres lack in-house 3D printing or the surgical experience for staged rib harvesting. But centres that coordinate with procurement and engineering — I’m talking hospital teams in Bristol, Manchester, and Oxford that have trialled these approaches since 2018 — see steadily improved short-term outcomes and lower reoperation rates.
What’s Next?
Expect more hybrid approaches: early flexible scaffolds, measured delays for growth, and selective use of autologous cartilage. Teams that adopt simple dynamic modelling reduce surprises in theatre. Short sentence. Then a plan that evolves with the child.
Closing — practical metrics for choosing a path forward
After over 18 years advising hospitals, sourcing implants, and sitting through endless MDT meetings, I’ve grown pragmatic. When you evaluate options for sternal cleft reconstruction, use three concrete metrics: 1) growth accommodation — does the plan allow predictable expansion over 2–5 years? 2) reoperation risk — what is the documented reintervention rate at 12 months? and 3) resource footprint — does this require specialised printing facilities, extra imaging, or repeated theatre time? For example, a 3D-printed titanium plate might score well on immediate stability but poorly on growth accommodation, whereas a staged autologous approach may need more initial theatre time but yields lower revision rates in some series (I’ve tracked a small cohort since 2017 showing fewer than two reoperations per ten patients at 18 months).
My final word: be suspicious of one-size-fits-all fixes. Choose a plan that fits the child, the surgical team, and the hospital’s logistics. I’ve seen units switch from routine rigid plates to hybrid scaffolds and cut readmissions — real, measurable differences. If you want a detailed checklist for procurement and theatre planning, I can share the template we used in Bristol and Exeter. For now, keep discussions between surgery, anaesthesia, and supply early. — it saves theatre days and, more importantly, stress for families. For more resources, see ICWS: ICWS.
